Innovation Investment: Genmab A/S vs. Perrigo Company plc

In the competitive landscape of pharmaceuticals, innovation is key. Over the past decade, Genmab A/S has consistently outpaced Perrigo Company plc in research and development (R&D) investments. From 2014 to 2023, Genmab's R&D expenses surged by over 1,400%, reaching a peak in 2023. In contrast, Perrigo's R&D spending remained relatively stable, with a slight decline of around 20% over the same period.

A Decade of Growth

Genmab's commitment to innovation is evident, with its R&D expenses growing from approximately 500 million in 2014 to a staggering 7.6 billion in 2023. This growth underscores Genmab's strategic focus on pioneering new treatments and therapies. Meanwhile, Perrigo's steady investment, peaking at 220 million in 2018, reflects a more conservative approach.

The Future of Innovation

As the pharmaceutical industry evolves, Genmab's aggressive R&D strategy positions it as a leader in innovation, while Perrigo may need to reassess its investment strategy to remain competitive.